Fidest – Agenzia giornalistica/press agency

Quotidiano di informazione – Anno 31 n°159

Posts Tagged ‘conferences’

Tetraphase Pharmaceuticals to Present at Upcoming Investor Conferences

Posted by fidest press agency su giovedì, 4 aprile 2019

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel tetracyclines to treat serious and life-threatening conditions, today announced that senior management will present a corporate overview at the H. C. Wainwright and Company Global Life Sciences Conference on Monday, April 8, 2019 at 9:10 a.m. GMT at the Grosvenor House JW Marriott Hotel in London, UK and at the 18th Annual Needham Healthcare Conference on Wednesday, April 10, 2019 at 2:50 p.m. ET at the Westin Grand Central Hotel in New York City.Live audio webcasts of both presentations will be available on the Company’s website at https://tphase.gcs-web.com/events-presentations. The archived presentation will be available for 30 days.
Tetraphase Pharmaceuticals, Inc., is a biopharmaceutical company using its proprietary chemistry technology to create novel tetracyclines for serious and life-threatening conditions, including bacterial infections caused by many of the multidrug-resistant bacteria highlighted as urgent public health threats by the World Health Organization and the Centers for Disease Control and Prevention. The Company has created more than 3,000 novel tetracycline compounds using its proprietary technology platform. Tetraphase’s lead product XERAVATM is approved for the treatment of complicated intra-abdominal infections by the U.S. Food and Drug Administration and the European Medicines Agency. The Company’s pipeline also includes TP-271 and TP-6076, which are in Phase 1 clinical trials and TP-2846 which is in preclinical testing for acute myeloid leukemia. Please visit http://www.tphase.com for more company information.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

bluebird bio to Present at Investor Conferences in March

Posted by fidest press agency su martedì, 12 marzo 2019

39th Annual Health Care Conference, Tuesday, March 12, at 8:40 am ET at the Boston Marriott Copley Place, Boston, MA
Barclays Global Healthcare Conference, Thursday, March 14, at 1:05 pm ET at the Loews Miami Beach Hotel, Miami Beach, FL
Alliance for Regenerative Medicine’s 7th Annual Cell & Gene Investor Day, Thursday, March 21, at 12:10 pm ET at the Metropolitan Club, New York, NYTo access the live webcasts of bluebird bio’s presentations, please visit the “Events & Presentations” page within the Investors & Media section of the bluebird bio website at http://investor.bluebirdbio.com. Replays of the webcasts will be available on the bluebird bio website for 90 days following the conferences.
bluebird bio is pioneering gene therapy with purpose. From our Cambridge, Mass., headquarters, we’re developing gene therapies for severe genetic diseases and cancer, with the goal that people facing potentially fatal conditions with limited treatment options can live their lives fully. Beyond our labs, we’re working to positively disrupt the healthcare system to create access, transparency and education so that gene therapy can become available to all those who can benefit.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Aura Biosciences to Present at Upcoming Investor Conferences

Posted by fidest press agency su sabato, 9 marzo 2019

Aura Biosciences, a leader in the development of novel targeted therapies in ocular oncology, today announced that management will present a company overview at the following investor conferences: Cowen and Company 39th Annual Health Care Conference on Tuesday, March 12, 2019, at 10:00 a.m. Eastern Time in Boston, MA
Oppenheimer’s 29th Annual Healthcare Conference on Tuesday, March 19, 2019, at 9:10 a.m. Eastern Time in New York, NY.
Aura Biosciences is developing a new class of therapies to selectively target and destroy cancer cells. Its lead program, AU-011 in primary choroidal melanoma, is being developed under a CRADA with the National Cancer Institute (NCI), part of the National Institutes of Health. For more information, visit http://www.aurabiosciences.com.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

ALX Oncology to Present Preclinical Data on SIRPα Antibody Program at Upcoming Conferences

Posted by fidest press agency su domenica, 3 marzo 2019

ALX Oncology, a clinical-stage immuno-oncology company developing therapies to block the CD47 checkpoint mechanism, today announced that preclinical data for its SIRPα antibody research program will be presented at the 2019 Keystone Symposia Conference (Keystone), Cancer Immunotherapy in Whistler, British Columbia and the American Association for Cancer Research (AACR) Annual Meeting 2019 in Atlanta, Georgia.CD47/SIRPα interaction is a key checkpoint mechanism exploited by cancer cells to escape immunological surveillance. While CD47 is widely expressed in human cells, SIRPα, the CD47 inhibitory receptor, is mainly expressed in myeloid cells and neurons. ALX148, a CD47 blocker with an inactive Fc domain, is generally well tolerated and demonstrates anti-cancer activity in combination with trastuzumab and pembrolizumab in patients with anti-HER2 and checkpoint inhibitor resistant/refractory disease (SITC 2018, P335). Another approach to block this interaction is to target SIRPα.“Targeting the CD47/SIRPα pathway is an exciting new approach that shows promise in clinical trials. By targeting SIRPα, we can investigate the similarities and differences of an orthogonal strategy to inhibit this axis,” said Hong Wan, Ph.D., ALX Oncology’s Chief Scientific Officer. “Our panel of proprietary high affinity monoclonal antibodies provides diverse epitope coverage across the extracellular surface of SIRPα. These antibodies are cross-reactive to human, monkey and rodent SIRPα variants, which enables robust clinical translation. Importantly, these antibodies bind to all human SIRPα variants, a critical attribute for a global patient population.” ALX Oncology’s SIRPα antibodies enhance the antitumor activity of immune checkpoint inhibitors, with reduction of metastases, eradication of tumors, and acquisition of memory immune response in tumor-bearing mice with intact immune systems. The cellular immune response in syngeneic models shows that these SIRPα antibodies enhance innate and adaptive anti-cancer immunity, providing a rationale for combination with other immunotherapies. In an exploratory toxicology study in monkeys, the selected SIRPα antibodies demonstrate a favorable pharmacokinetic, target occupancy and tolerability profile.Together, these preclinical data provide a compelling rationale to advance the development of anti-SIRPα therapy for patients with cancer.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Dicerna Pharmaceuticals to Present at Upcoming Investor Conferences

Posted by fidest press agency su giovedì, 28 febbraio 2019

Dicerna Pharmaceuticals, Inc. (Nasdaq:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will present a corporate overview at the following investor conferences in March:
8th Annual Leerink Partners Global Healthcare Conference in New York on Friday, March 1, 2019 at 9 a.m. ET.
Cowen and Company 39th Annual Healthcare Conference in Boston on Tuesday, March 12, 2019 at 8 a.m. ET.
A live audio webcast of both presentations can be accessed on the Investors and Media section of the Dicerna website at http://www.investors.dicerna.com. Archived replays will be available on the Company’s website for a period of 90 days after each conference.
Dicerna Pharmaceuticals, Inc., is a biopharmaceutical company focused on the discovery and development of innovative, subcutaneously delivered RNAi-based therapeutics for the treatment of diseases involving the liver, including rare diseases, chronic liver diseases, cardiovascular diseases and viral infectious diseases. Dicerna is leveraging its proprietary GalXC™ RNAi technology platform to build a broad pipeline in these core therapeutic areas, focusing on target genes where connections between target gene and diseases are well understood and documented. Dicerna intends to discover, develop and commercialize novel therapeutics either on its own or in collaboration with pharmaceutical partners. Dicerna has strategic collaborations with Eli Lilly and Company, Alexion Pharmaceuticals, Inc. and Boehringer Ingelheim International GmbH. For more information, please visit http://www.dicerna.com.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

RealPage to Participate in Upcoming Investor Conferences

Posted by fidest press agency su lunedì, 25 febbraio 2019

RealPage, Inc. (NASDAQ:RP), a leading global provider of software and data analytics to the real estate industry, today announced that Steve Winn, Chairman and CEO, will present at the JMP Securities 2019 Technology Conference, to be held in San Francisco on February 26, 2019 at 2:30 p.m. PT. Winn will also present on behalf of RealPage at the Morgan Stanley Technology, Media & Telecom Conference, to be held in San Francisco on February 27, 2019 at 1:30 p.m. PT. Both presentations will be webcast live on the Investor Relations section of the Company’s Web site at http://www.realpage.com.

Posted in Estero/world news | Contrassegnato da tag: , | Leave a Comment »

ObsEva SA to Participate in Upcoming Investor Conferences

Posted by fidest press agency su domenica, 24 febbraio 2019

Geneva, Switzerland and Boston, ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy, today announced that Company Management will be participating in two upcoming investor conferences. The SVB Leerink Global Healthcare Conference taking place in New York February 27-March 1, 2019. ObsEva will present on Thursday, February 28, 2019, at 3 p.m. Eastern Time.
The Jefferies Global Healthcare Summit taking place in Zurich, Switzerland on March 8, 2019. ObsEva will present on Friday, March 8, 2019 at 3:45 p.m. Central European Time.
ObsEva is a clinical-stage biopharmaceutical company focused on the clinical development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on treating endometriosis, uterine fibroids, preterm labor and improving IVF outcomes. ObsEva is listed on the NASDAQ Global Select Market and is trading under the ticker symbol “OBSV” and on the SIX Swiss Exchange where it is trading under the ticker symbol “OBSN”. For more information, please visit http://www.ObsEva.com.

Posted in Estero/world news | Contrassegnato da tag: , | Leave a Comment »

New Relic to Present at Upcoming Investor Conferences

Posted by fidest press agency su domenica, 10 febbraio 2019

New Relic, Inc. (NYSE:NEWR), provider of real-time insights for software-driven businesses, today announced that Chief Financial Officer Mark Sachleben will present at the following upcoming investor conferences:
Goldman Sachs Technology and Internet Conference in San Francisco on Tuesday, February 12, 2019, at 11:00 a.m. PT.
JMP Securities Technology Conference in San Francisco on Tuesday, February 26, 2019, at 2:00 p.m. PT.
Morgan Stanley Technology, Media & Telecom Conference in San Francisco on Wednesday, February 27, 2019, at 2:40 p.m. PT.
Raymond James 40th Annual Institutional Investors Conference in Orlando on Wednesday, March 6, 2019, at 9:50 a.m. ET.
Live webcasts of the presentations will be accessible from the investor relations page of the New Relic website at http://ir.newrelic.com. Following the events, replays will be made available at the same location.
New Relic provides the real-time insights that software-driven businesses need to innovate faster. New Relic’s cloud platform makes every aspect of modern software and infrastructure observable, so companies can find and fix problems faster, build high-performing DevOps teams, and speed up transformation projects. Learn why more than 50% of the Fortune 100 trust New Relic at newrelic.com.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Zayo Executives to Present at December Investor Conferences

Posted by fidest press agency su domenica, 2 dicembre 2018

Zayo Group Holdings, Inc. (NYSE: ZAYO) announced today that executives from the company will present at two investor conferences in December. The links to the live webcasts for the conferences will be made available through the Investor Relations section of the Company’s website at: http://investors.zayo.com.Dan Caruso, chairman and CEO, will present at the UBS Global Media and Communications Conference at the Grand Hyatt in New York on Tuesday, December 4, 2018. The presentation will be webcast live at 9:30 a.m. EST.Matt Steinfort, CFO, will present at the Barclays Global Technology, Media and Telecommunications Conference at The Palace Hotel in San Francisco on Thursday, December 6, 2018. The presentation will be webcast live at 11:30 a.m. PST.
Zayo Group Holdings, Inc. (NYSE: ZAYO) provides communications infrastructure solutions, including fiber and bandwidth connectivity, colocation and cloud infrastructure to the world’s leading businesses. Customers include wireless and wireline carriers, media and content companies and finance, healthcare and other large enterprises. Zayo’s 130,000-mile network in North America and Europe includes extensive metro connectivity to thousands of buildings and data centers. In addition to high-capacity dark fiber, wavelength, Ethernet and other connectivity solutions, Zayo offers colocation and cloud infrastructure in its carrier-neutral data centers. Zayo provides users with flexible, customized solutions and self-service through Tranzact, an innovative online platform for managing and purchasing bandwidth. For more information, visit zayo.com.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Media Alert: Rambus to Present at Credit Suisse and Barclays Investor Conferences

Posted by fidest press agency su giovedì, 22 novembre 2018

Rambus Inc. (Nasdaq: RMBS) announced today that Luc Seraphin, chief executive officer, and Rahul Mathur, chief financial officer, will present at two upcoming investor events.
Credit Suisse 22nd Annual Technology, Media and Telecom Conference in Scottsdale, AZ on Wednesday, November 28, 2018 at 10:00 a.m. MT.
Barclays 2018 Global Technology, Media and Telecommunications Conference in San Francisco, CA on Wednesday, December 5, 2018 at 2:30 p.m. PT.
The presentations will be available through a webcast which can be accessed on the Rambus Investor Relations website at investor.rambus.com. A replay of each presentation will also be available on the website following the events.
Dedicated to making data faster and safer, Rambus creates innovative hardware, software and services that drive technology advancements from the data center to the mobile edge. Our architecture licenses, IP cores, chips, software, and services span memory and interfaces, security, and emerging technologies to positively impact the modern world. We collaborate with the industry, partnering with leading chip and system designers, foundries, and service providers. Integrated into tens of billions of devices and systems, our products and technologies power and secure diverse applications, including Big Data, Internet of Things (IoT) security, mobile payments, and smart ticketing. For more information, visit rambus.com.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Revance to Participate in Upcoming Investor Conferences

Posted by fidest press agency su giovedì, 22 novembre 2018

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that the Company will participate in two upcoming investor conferences.President and Chief Executive Officer, Dan Browne, is scheduled to participate in a fireside discussion at the Evercore ISI, HealthCONx in Boston, MA on Tuesday, November 27 at 4:15pm ET.President and Chief Executive Officer, Dan Browne, is also scheduled to participate in a fireside discussion at the Piper Jaffray 30th Annual Healthcare Conference in New York, NY on Wednesday, November 28 at 12:30pm ET.Interested parties can access the live audio webcasts for both conferences from the Investor Relations section of the company’s website at http://www.revance.com. The webcast replays will be available after the conclusion of the live fireside discussions for approximately 30 days.
Revance Therapeutics is an emerging Silicon Valley biotechnology leader developing neuromodulators for the treatment of aesthetic and therapeutic conditions. Revance uses a unique proprietary, stabilizing excipient peptide technology to create novel, differentiated therapies. The company’s lead compound, DaxibotulinumtoxinA for Injection (RT002), is in clinical development for a broad range of aesthetic and therapeutic indications, including glabellar lines, cervical dystonia, plantar fasciitis, upper limb spasticity and chronic migraine. RT002 has the potential to be the first long-acting neuromodulator. The company is advancing a robust pipeline of injectable and topical formulations of DaxibotulinumtoxinA. More information on Revance may be found at http://www.revance.com.

Posted in Estero/world news | Contrassegnato da tag: , , , | Leave a Comment »

Hanger to Present at Upcoming Investor Conferences

Posted by fidest press agency su sabato, 17 novembre 2018

Hanger, Inc. (NYSE: HNGR), a leading provider of orthotic and prosthetic patient care services and solutions, announced today that management will participate in presentations and meetings with institutional investors at the following conferences:
The Credit Suisse 27th Annual Healthcare Conference, being held November 12-15 at The Phoenician in Scottsdale, Arizona. The investor presentation is scheduled for Thursday, November 15, 2018, beginning at 10:35 a.m. Eastern time. The presentation will be available via webcast on the investor relations section of the Company’s website, http://www.investor.hanger.com, and a replay will be available for 90 days.The Company will present at the Bank of America Merrill Lynch 2018 Leveraged Finance Conference, to be held at the Boca Raton Resort and Club, Boca Raton, Florida. The investor presentation is scheduled for Wednesday, December 5, 2018, beginning at 7:30 a.m. Eastern time. The presentation and replay will be available via webcast, per the information above.
The Company will also present at the CJS 19th Annual Investor Conference to be held Wednesday, January 9, 2019, at the Four Seasons Hotel in New York City. The presentation time has not yet been scheduled.
About Hanger, Inc. – Built on the legacy of James Edward Hanger, the first amputee of the American Civil War, Hanger, Inc. (NYSE: HNGR) delivers orthotic and prosthetic (O&P) patient care, and distributes O&P products and rehabilitative solutions to the broader market. Hanger’s Patient Care segment is the largest owner and operator of O&P patient care clinics with approximately 800 patient care locations nationwide. Through its Products & Services segment, Hanger distributes branded and private label O&P devices, products and components, and provides rehabilitative solutions. With over 150 years of clinical excellence and innovation, Hanger’s vision is to lead the orthotic & prosthetic markets by providing superior patient care, outcomes, services and value. For more information on Hanger, visit http://www.hanger.com.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Zendesk To Present At Upcoming Investor Conferences

Posted by fidest press agency su venerdì, 9 novembre 2018

Marc Cabi, Vice President of Strategy and Head of Investor Relations, will present at the UBS Global Technology Conference in San Francisco, California on Wednesday, November 14, 2018. Zendesk’s presentation is scheduled for 8:45 a.m., Pacific Time.
Tom Keiser, Chief Operating Officer, will present at the Wells Fargo Tech Summit in Park City, Utah on Tuesday, December 4, 2018. Zendesk’s presentation is scheduled for 2:20 p.m., Mountain Time.A live webcast of each presentation will be accessible by visiting Zendesk’s investor website at investor.zendesk.com. An archived version will be available for six months.
The best customer experiences are built with Zendesk. Zendesk’s powerful and flexible customer service and engagement platform scales to meet the needs of any business, from startups and small businesses to growth companies and enterprises. Zendesk serves businesses across a multitude of industries, with more than 125,000 paid customer accounts offering service and support in more than 30 languages. Headquartered in San Francisco, Zendesk operates worldwide with 16 offices in North America, Europe, Asia, Australia, and South America. Learn more at http://www.zendesk.com.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

AVEO Oncology to Participate in Upcoming Conferences

Posted by fidest press agency su mercoledì, 26 settembre 2018

AVEO Pharmaceuticals, Inc. (the “Company”) is a biopharmaceutical company dedicated to advancing a broad portfolio of targeted medicines for oncology and other areas of unmet medical need. The Company’s strategy is to retain North American rights to its oncology portfolio while securing partners in development and commercialization outside of North America. The Company is seeking to develop and commercialize its lead candidate tivozanib in North America as a treatment for advanced renal cell carcinoma (“RCC”). The Company has outlicensed tivozanib (FOTIVDA®) for oncology in Europe and other territories outside of North America. Tivozanib is approved in the European Union, as well as Norway and Iceland, for the first-line treatment of adult patients with RCC and for adult patients who are vascular endothelial growth factor receptor and mTOR pathway inhibitor-naïve following disease progression after one prior treatment with cytokine therapy for RCC. The Company has entered into partnerships to fund the development and commercialization of AV-203 (CAN017) and ficlatuzumab, both clinical stage assets in oncology. The Company is currently seeking a partner to develop the AV-353 platform, a preclinical asset, worldwide for the potential treatment of pulmonary arterial hypertension. The Company has recently regained the rights to its AV-380 program for the potential treatment of cachexia and is considering a variety of options to advance the program’s development. http://www.aveooncology.com.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

American Express Executives to Participate in Upcoming Conferences

Posted by fidest press agency su domenica, 9 settembre 2018

American Express (NYSE:AXP) Chief Financial Officer, Jeffrey C. Campbell, will participate in the Barclays Global Financial Services Conference in New York City, on Wednesday, September 12, 2018, at 12:00 p.m. (ET). Mr. Campbell will participate in a question-and-answer session relating to the company’s business strategy and financial performance.Additionally, American Express Group President of Global Consumer Services, Douglas E. Buckminster, will participate in the Autonomous Research Future of Commerce Symposium in New York City, on Thursday, September 20,2018 at 2:05 p.m. (ET). Mr. Buckminster will participate in a question-and-answer session relating to the company’s global consumer business.Live audio webcasts of both events will be accessible to the general public through the American Express Investor Relations website at http://ir.americanexpress.com. An audio replay of each presentation will be available after the event at the same website address.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

The Meet Group to Speak at RTC and CHina CHat Conferences

Posted by fidest press agency su domenica, 9 settembre 2018

The Meet Group, Inc. (NASDAQ:MEET), a public market leader in the mobile meeting space, announced today that CFO, Jim Bugden and SVP of Engineering, Richard Friedman will speak at RTC September 7-8, 2018 and newly appointed VP of Livestreaming, Lauren Hallanan, will speak at CHina CHat September 20-21, 2018. RTC, also known as Real Time Web Solutions Conference, explores the countless ways companies are expanding their footprints through the use of real-time communications. The event will take place at The Great Wall Hotel in Beijing, China where Bugden will present on the social-entertainment trends in North America on Friday, September 7 at 2:30 pm and Friedman will keynote on the main stage at 9:30 am on Saturday, September 8.”I am very excited by the opportunity to talk about our video use case in front of this audience who helped create the standards that make it possible,” said Friedman. “We could not have scaled from one US application to four global brands without this technology.”
CHina CHat is a 2-day conference dedicated to WeChat and China digital marketing for international companies and is located at The Place in Shanghai, China. Hallanan is scheduled to participate in a panel discussion and host a break out session focusing on the influencer marketing industry in China on Friday, September 21.“CHina CHat attracts hundreds of the top minds in China’s social media and tech industries,” said Hallanan. “I’m looking forward to strengthening relationships and making new connections. It will be a great opportunity to share the growth of The Meet Group with the China community.”Before joining The Meet Group, Hallanan worked as a livestreaming consultant for The Meet Group giving an insider’s perspective on the growth and success of Momo and other Chinese livestreaming applications. Hallanan was also a top streamer on a number of Chinese platforms from 2016-2017 when she lived in Beijing, China. In her new position, Lauren will continue to advise on product and also manage external outreach related to the company’s livestreaming platform.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

RingCentral to Participate in Upcoming Investor Conferences

Posted by fidest press agency su lunedì, 3 settembre 2018

RingCentral, Inc. (NYSE:RNG), a leading provider of global enterprise cloud communications and collaboration solutions, today announced that the company will be participating in the following investor events. David Sipes, Chief Operating Officer will be participating at:
Dougherty & Company 3rd Annual Institutional Investor Conference in Minneapolis, MN, on Thursday, September 6, 2018.
Vlad Shmunis, Founder, Chairman, and Chief Executive Officer, and Mitesh Dhruv, Chief Financial Officer will be presenting at:
Deutsche Bank Technology Conference, in Las Vegas, NV, on Wednesday, September 12, 2018 at 2:30 p.m. PT. Live webcast, as well as a replay, of the presentation will be accessible from the investor relations page of the RingCentral website at http://ir.ringcentral.com/.

Posted in Estero/world news | Contrassegnato da tag: , , , | Leave a Comment »

Epizyme to Participate in Upcoming Investor Conferences

Posted by fidest press agency su sabato, 1 settembre 2018

New York. Epizyme, Inc. (NASDAQ: EPZM), a clinical-stage company developing novel epigenetic therapies, today announced that management will present at the following upcoming investor conferences: Citi’s 13th Annual Biotech Conference in Boston – Panel discussion at 3:15 p.m. ET on Wednesday, September 5, 2018.
Morgan Stanley’s 16th Annual Global Healthcare Conference in New York City – Fireside chat at 2:50 p.m. ET on Wednesday, September 12, 2018
Leerink Partners 2018 Rare Disease & Oncology Roundtable in New York City – Fireside chat at 10:00 a.m. ET on Wednesday, October 3, 2018
To access a live webcast of these presentations, please visit the Events & Presentations page within the Investor section of the company’s website at http://www.epizyme.com. A replay of each webcast will be available on the Epizyme website for 60 days following the event.
Epizyme, Inc. is a clinical-stage biopharmaceutical company committed to rewriting treatment for cancer and other serious diseases through novel epigenetic medicines. Epizyme is broadly developing its lead product candidate, tazemetostat, a first-in-class EZH2 inhibitor, with studies underway in both solid tumors and hematological malignancies, as a monotherapy and combination therapy in relapsed and front-line disease. The company is also developing a novel G9a program with its next development candidate, EZM8266, which is targeting sickle cell disease. By focusing on the genetic drivers of disease, Epizyme’s science seeks to match targeted medicines with the patients who need them. For more information, visit http://www.epizyme.com.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Avnet to Present at Citi and Deutsche Bank Financial Conferences in September

Posted by fidest press agency su lunedì, 27 agosto 2018

Avnet (Nasdaq: AVT), a leading global technology solutions provider, today announced that two of its senior executives will participate in the Citi 2018 Global Technology Conference and the Deutsche Bank 2018 Technology Conference, both of which will take place in September.
Bill Amelio, Chief Executive Officer, and Tom Liguori, Chief Financial Officer, will participate in the Citi 2018 Global Technology Conference on Wednesday, September 5. The fireside chat will start at 1:30 p.m. EDT at the New York Hilton Midtown Hotel.Tom Liguori will also present at the Deutsche Bank 2018 Technology Conference to be held at The Bellagio in Las Vegas, on Wednesday, September 12, at 4:30 p.m. PDT. Both presentations will be webcast live at https://ir.avnet.com/events-presentations. Interested parties should log on to the Avnet Investor Relations 10 minutes prior to the presentation time to register for the event.
From idea to design and from prototype to production, Avnet supports customers at each stage of a product’s lifecycle. A comprehensive portfolio of design and supply chain services makes Avnet the go-to guide for innovators who set the pace for technological change. For nearly a century, Avnet has helped its customers and suppliers around the world realize the transformative possibilities of technology. Learn more about Avnet at http://www.avnet.com. (AVT_IR)

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Arcus Biosciences Announces Participation at Two Investor Conferences in September

Posted by fidest press agency su lunedì, 27 agosto 2018

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, today announced the Company will be participating in the following upcoming investor conferences: Citi’s 13th Annual Biotech Conference in Boston on Wednesday, September 5, 2018. At 3:15 pm ET, Terry Rosen, Ph.D., Chief Executive Officer, will participate in a panel discussion entitled, “Targeted Therapies Oncology – Aiming for the Bull’s Eye.” Morgan Stanley 16th Annual Global Healthcare Conference in New York City on Thursday, September 13, 2018. At 4:40 pm ET, Terry Rosen, Ph.D., Chief Executive Officer, and Jennifer Jarrett, Chief Operating Officer and Chief Financial Officer, will participate in a fireside chat. Individuals may access the live audio webcast of the fireside chat by visiting the “Events & Presentations” section of the Company’s website at https://investors.arcusbio.com/investors/events-and-presentations. A replay of the webcast will be available for 30 days following the live event.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »